Table 1.
Patient characteristics
| Age (Mean ± SD) | 45.9 ± 11.1 | Disease, N (%) | |
|---|---|---|---|
|
BMI (Mean ± SD) |
32 ± 8.2 |
Inactive |
45 (28) |
|
Gender, N (%) |
|
Active/Symptomatic† |
117 (72) |
| Male |
45 (28) |
Organ Involvements N (%) |
|
| Female |
117 (72) |
Lung |
152 (94) |
|
Race, N (%) |
|
Skin |
49 (30) |
| African American |
139 (86.8) |
Eye |
43 (26) |
| White |
21(13.2) |
Heart |
11 (6) |
|
CXR stage, N (%) |
|
Liver |
18 (11) |
| 0 |
13 (8.2) |
CNS |
13 (6) |
| 1 |
28 (17.7) |
PH* |
28 (17) |
| 2 |
65 (41.5) |
Medication, N (%) |
|
| 3 |
24 (14) |
Steroidal |
94 (58) |
| 4 |
29(18.2) |
IMD‡ |
68 (42) |
| Non-smokers | 123 (76) | Steroidal + IMD | 77 (47) |
Values are means unless otherwise noted. N = number of patients, parenthesis = percent.
*PH: pulmonary hypertension, diagnosed by right cardiac catheterization.
† Active defined as an increased requirement for steroid in last 6 months.
‡ Immune modifying drugs like methotrexate, azathioprine and others.